about
Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's diseaseAzathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's diseaseOral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's diseaseAminosalicylates for induction of remission or response in Crohn's diseaseOral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's diseaseAminosalicylates for induction of remission or response in Crohn's diseaseEvidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanBudesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trialsSevere and steroid-resistant Crohn's diseaseOral budesonide in the management of Crohn's disease.Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.Gastroparesis in patients with inactive Crohn's disease: a case series.Systems analysis of inflammatory bowel disease based on comprehensive gene information.Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.The effectiveness of budesonide therapy for Crohn's disease.Colonic inflammatory bowel disease. Medical therapies for colonic Crohn's disease and ulcerative colitis.Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activityThe Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA.The promise of metabolic phenotyping in gastroenterology and hepatology.Review article: aminosalicylates in inflammatory bowel disease.Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease.Therapy of mild to moderate luminal Crohn's disease.Severe and steroid-resistant Crohn's disease.Maintenance of remission in Crohn's disease.Bacopa monnieri Extract (CDRI-08) Modulates the NMDA Receptor Subunits and nNOS-Apoptosis Axis in Cerebellum of Hepatic Encephalopathy RatsVedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison.Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.Gut inflammation in the spondyloarthropathies.Are patients with inflammatory bowel disease receiving optimal care?Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.Bone loss in Crohn's disease: exercise as a potential countermeasure.What's new: innovative concepts in inflammatory bowel disease.Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.Management consensus of inflammatory bowel disease for the Asia-Pacific region.Management of inflammatory bowel disease in adults.
P2860
Q24194516-03C77ACF-33FE-4849-841D-67AC6E1FA3DAQ24197910-EB7C0C28-7DF7-428F-ADC8-C0C366C9CAF2Q24234938-609C129B-C25C-4BB7-B410-401DD95D8911Q24235730-D5D83DA2-8816-4D80-ACBD-4FF347B43FBAQ24239841-29DE8F05-6CD3-414D-891F-3BAEBF9F0595Q26471183-7BE6F380-AE7B-4B8E-9E46-ECDB98F9C6C9Q26829392-23B6BA33-F735-40D4-A129-59D641C0E466Q28266279-4A83CECF-98B2-4CE7-A918-0AD67CC05F34Q28266806-70E62513-FFBF-4E9C-AA64-EC37CA8FDE5CQ30311870-4A717082-5E8E-4EB3-9539-BDB78268E8EAQ33268021-4C8906DA-B061-497E-95E1-3CEC31DEC257Q33279571-109C28AE-ABF9-4436-8067-9DD10B5D78E6Q34223105-D3D19C6C-6139-4D11-8FB6-BD021B23551FQ34553531-A414C34D-2216-4692-BCAE-6B32298B4C1CQ34636098-B14D2D1D-649C-44C7-97C2-18ABF82F18E9Q34786715-2C255D34-CE31-41BF-87C4-F82B1DFB919DQ35014539-6998B1BF-E390-44FB-9445-FBF115DCD949Q35030557-8E1AE2F5-CD46-4A18-A3BE-977DAC197E80Q35190662-EA23D5F3-ABD9-4853-93C1-393357A06F47Q35605835-8ED16E0F-4EC9-4312-A5F3-071BA05D3C7BQ35634736-0A2923B2-2B19-447B-94F7-FCD936CDF02CQ35701279-6EB34A24-EF47-4467-96B2-8B1A468F4F26Q35880396-D80BB156-137C-4BCF-A70F-3822635AA655Q35913934-801B7CA5-64B0-4B54-B1D1-3AD243E3BB27Q36041698-69396643-6BDD-4335-8249-88A1EC652A9FQ36041702-CADA1FDD-ECA7-425C-BE19-9DEB0EF0F187Q36041732-AFA219B0-52FB-4A1B-B8DE-003D02B047DFQ36043633-D3B9C4A0-1F72-4E5F-A85F-0A08660A8844Q36049752-09CB8022-9B86-403C-BC15-771B301A36AAQ36072580-F4279C9B-C9BA-4F45-9E1A-5143100F554DQ36140805-0EB221FC-A4F2-4EED-B85A-60A19138A327Q36147333-B0A3A29D-14D7-4C3F-95C6-4ECC453E1ABDQ36177695-E94EF053-F8FC-4517-8472-B59C8632D57CQ36223905-99758577-4362-4388-B59F-DF228FF28FE6Q36321697-9325BDAE-09EB-4F3E-BF51-3700F345FF69Q36440535-1CEC8A9C-7A7A-4FE0-AE9C-BC8185397E40Q36555966-C6E9A695-DCEB-4F5D-9967-1DAE8B3C2748Q36598119-68E01423-1F98-4DCB-A1AD-CF95FFB39B4AQ36639081-F2F8FA1F-3C5D-47B3-8087-5244BDE6C885Q36833342-5E3629F1-2132-4913-B242-4D57815748FA
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Management of Crohn's disease in adults
@ast
Management of Crohn's disease in adults
@en
type
label
Management of Crohn's disease in adults
@ast
Management of Crohn's disease in adults
@en
prefLabel
Management of Crohn's disease in adults
@ast
Management of Crohn's disease in adults
@en
P1476
Management of Crohn's disease in adults
@en
P2093
Stephen B. Hanauer
William Sandborn
P2860
P304
P356
10.1111/J.1572-0241.2001.03671.X
P407
P577
2001-03-01T00:00:00Z